Mycoster (R)

Phase 3Small molecule

UUniversity Hospital, Rouen

Mycoster (R) is one of 20 small molecule programs targeting Seborrheic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Seborrheic DermatitisActive, not recruiting

Seborrheic DermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Seborrheic Dermatitis

#DrugCompanyPhaseTrials

Daliresp

Jakafi

Prograf

VVeloxis Pharmaceuticals

Approved

1 4

Eucrisa

AAnacor

Approved

1 5

Rayos

RRoxane Laboratories

Approved

—6

Elidel

BBausch Health Americas, Inc.

Approved

—7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—8

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—9

Decadron

AAspen Global Incorporated

Nizoral

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seborrheic Dermatitis1 trial

Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Completed·UUniversity Hospital, Rouen·Phase 3·NCT02004860·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mycoster (R). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycoster (R) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycoster (R). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Rouen

Mycoster (R)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seborrheic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News